SMT202400518T1 - Composizioni anticancro - Google Patents
Composizioni anticancroInfo
- Publication number
- SMT202400518T1 SMT202400518T1 SM20240518T SMT202400518T SMT202400518T1 SM T202400518 T1 SMT202400518 T1 SM T202400518T1 SM 20240518 T SM20240518 T SM 20240518T SM T202400518 T SMT202400518 T SM T202400518T SM T202400518 T1 SMT202400518 T1 SM T202400518T1
- Authority
- SM
- San Marino
- Prior art keywords
- cancer compositions
- cancer
- compositions
- Prior art date
Links
- 230000001093 anti-cancer Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196594 | 2014-12-05 | ||
| EP15817641.2A EP3226841B1 (en) | 2014-12-05 | 2015-12-03 | Anticancer compositions |
| PCT/US2015/063661 WO2016090098A1 (en) | 2014-12-05 | 2015-12-03 | Anticancer compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT202400518T1 true SMT202400518T1 (it) | 2025-01-14 |
Family
ID=52006906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20240518T SMT202400518T1 (it) | 2014-12-05 | 2015-12-03 | Composizioni anticancro |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20170360754A1 (enExample) |
| EP (2) | EP3226841B1 (enExample) |
| JP (2) | JP6937692B2 (enExample) |
| KR (2) | KR102348320B1 (enExample) |
| CN (2) | CN114886852A (enExample) |
| AR (1) | AR102926A1 (enExample) |
| AU (3) | AU2015358490B2 (enExample) |
| BR (1) | BR112017011788A2 (enExample) |
| CA (1) | CA2969656A1 (enExample) |
| CL (1) | CL2017001371A1 (enExample) |
| CO (1) | CO2017005572A2 (enExample) |
| CR (1) | CR20170216A (enExample) |
| EA (1) | EA201791222A1 (enExample) |
| ES (1) | ES2996833T3 (enExample) |
| HR (1) | HRP20241719T1 (enExample) |
| HU (1) | HUE069689T2 (enExample) |
| IL (2) | IL252323B (enExample) |
| MA (1) | MA41107B1 (enExample) |
| MD (1) | MD3226841T2 (enExample) |
| MX (2) | MX387933B (enExample) |
| NZ (1) | NZ770528A (enExample) |
| PH (1) | PH12017500964A1 (enExample) |
| PL (1) | PL3226841T3 (enExample) |
| RS (1) | RS66323B1 (enExample) |
| SG (1) | SG11201704267VA (enExample) |
| SM (1) | SMT202400518T1 (enExample) |
| TW (2) | TWI754258B (enExample) |
| UA (1) | UA120950C2 (enExample) |
| WO (1) | WO2016090098A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014052237A1 (en) | 2012-09-26 | 2014-04-03 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| CN114886852A (zh) | 2014-12-05 | 2022-08-12 | 阿拉贡药品公司 | 抗癌组合物 |
| RS62421B1 (sr) | 2014-12-05 | 2021-10-29 | Aragon Pharmaceuticals Inc | Anti-kancerogeni sastavi |
| KR20240096623A (ko) | 2017-10-16 | 2024-06-26 | 아라곤 파마슈티컬스, 인코포레이티드 | 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐 |
| WO2020144649A1 (en) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Pharmaceutical composition comprising enzalutamide dispersed in apple sauce |
| KR20210122275A (ko) | 2019-01-30 | 2021-10-08 | 얀센 파마슈티카 엔.브이. | 분자 아형에 기초하여 전립선암을 치료하는 방법 |
| SG11202107712SA (en) | 2019-01-30 | 2021-08-30 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
| WO2020239478A1 (en) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectedin for treating sarcomas based on genomic markers |
| EP3811932A1 (en) | 2019-10-22 | 2021-04-28 | Zentiva K.S. | Dosage form of apalutamide |
| DK4054572T3 (da) | 2019-11-04 | 2026-08-03 | Aragon Pharmaceuticals Inc | Apalutanid til behandling af ikke-metastatisk kastrationsresistent prostatacancer hos subjekter med svært nedsat leverfunktion |
| WO2021245285A1 (en) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| WO2022049523A1 (en) | 2020-09-04 | 2022-03-10 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| WO2022195407A1 (en) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| WO2023122842A1 (es) * | 2021-12-31 | 2023-07-06 | Gador Limitada | Proceso para la preparación de apalutamida, intermediarios de sintesis y la dispersion solida amorfa que la contiene |
| WO2023152611A1 (en) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
| WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
| CN116183787A (zh) * | 2022-12-26 | 2023-05-30 | 郑州德迈药业有限公司 | 醋酸羟丙甲纤维素琥珀酸酯在阿帕他胺溶出检测中的应用以及检测方法 |
| JP2026515598A (ja) | 2023-03-16 | 2026-05-19 | バイエル・コンシューマー・ケア・アクチェンゲゼルシャフト | ホルモン感受性前立腺がんの生化学的再発を有する患者の処置のためのアンドロゲン受容体アンタゴニスト |
| AU2025209171A1 (en) * | 2024-01-18 | 2026-05-28 | Nanoform Finland Oyj | Composition comprising crystalline nanosized apalutamide |
| WO2025174375A1 (en) * | 2024-02-15 | 2025-08-21 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
| WO2026052846A1 (en) | 2024-09-09 | 2026-03-12 | Synthon B.V. | Pharmaceutical formulation comprising apalutamide |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2138618T3 (es) | 1992-03-31 | 2000-01-16 | Btg Int Ltd | Esteroides 17-sustituidos utiles en el tratamiento del cancer. |
| PT901786E (pt) * | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
| AU2001232348A1 (en) | 2000-02-21 | 2001-08-27 | Takeda Chemical Industries Ltd. | Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same |
| CZ20032225A3 (cs) | 2001-02-27 | 2003-11-12 | Astrazeneca Ab | Farmaceutická formulace |
| CZ20032647A3 (cs) | 2001-04-02 | 2004-09-15 | Astrazeneca Ab | Pevná farmaceutická kompozice obsahující 4-kyanotrifluor-3-(4-fluorfenylsulfonyl)-2-hydroxy-2-methylpropiono-m-toluidin a PVP |
| CA2450762A1 (en) * | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers |
| SE0103424D0 (sv) * | 2001-10-15 | 2001-10-15 | Astrazeneca Ab | Pharmaceutical formulation |
| EP1469830A2 (en) * | 2002-02-01 | 2004-10-27 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles |
| JPWO2003077827A1 (ja) | 2002-03-19 | 2005-07-14 | 日本新薬株式会社 | 医薬固体分散体の製造方法 |
| JP2007518670A (ja) | 2003-12-15 | 2007-07-12 | カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ | 苦味のある薬物、及びｐＨ感受性ポリマーを含む風味マスクされた医薬組成物 |
| GB0502790D0 (en) | 2005-02-10 | 2005-03-16 | Univ London Pharmacy | Solid dispersion of hydrophobic bioactive |
| NZ564223A (en) | 2005-05-13 | 2011-03-31 | Univ California | Diarylhydantoin compounds for treating hormone refractory prostate cancer |
| BRPI0709771B1 (pt) * | 2006-03-27 | 2022-01-25 | The Regents Of The University Of California | Composto e composição farmacêutica |
| CA2738573C (en) | 2009-04-03 | 2013-02-19 | F. Hoffmann-La Roche Ag | Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof |
| EP3124481B1 (en) | 2010-02-16 | 2018-03-28 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| CN102525876B (zh) | 2010-12-15 | 2014-03-12 | 西安力邦医药科技有限责任公司 | 阿司匹林固体分散体、其制备方法、药物组合物和用途 |
| CA2839301C (en) | 2011-06-15 | 2021-02-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
| US20150037407A1 (en) | 2012-03-21 | 2015-02-05 | Emphascience, Inc. | Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy |
| WO2013152342A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| UA123142C2 (uk) | 2012-06-07 | 2021-02-24 | Арагон Фармасьютікалз, Інк. | Кристалічні форми модулятора андрогенного рецептора |
| US10668156B2 (en) | 2012-06-22 | 2020-06-02 | Basf Se | Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers |
| BR112015002055A2 (pt) * | 2012-08-24 | 2017-07-04 | Dow Global Technologies Llc | acetato succinato de hidroxialquil metil celulose, composição, dispersão sólida, processo para produzir uma dispersão sólida, forma de dosagem e cápsula de envoltório |
| US9977033B2 (en) | 2012-09-11 | 2018-05-22 | The Board Of Regents Of The University Of Texas System | Methods for assessing cancer recurrence |
| TWI673051B (zh) | 2012-09-11 | 2019-10-01 | 美商梅維森前列腺療法有限責任公司 | 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物 |
| WO2014052237A1 (en) | 2012-09-26 | 2014-04-03 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| EP2945628B1 (en) | 2013-01-15 | 2020-04-15 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer |
| NZ708272A (en) | 2013-01-22 | 2020-07-31 | Hoffmann La Roche | Pharmaceutical composition with improved bioavailability |
| TWI686212B (zh) | 2013-03-15 | 2020-03-01 | 阿聯商太陽法瑪全球有限公司 | 醋酸阿比特龍配方 |
| WO2014167428A2 (en) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| KR20160058774A (ko) * | 2013-08-12 | 2016-05-25 | 토카이 파마슈티컬, 아이엔씨. | 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커 |
| WO2015116696A1 (en) | 2014-01-28 | 2015-08-06 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| CN106102716A (zh) | 2014-02-05 | 2016-11-09 | 斯洛文尼亚莱柯制药股份有限公司 | 雄激素受体拮抗剂的固体药物组合物 |
| TWI718102B (zh) | 2014-08-08 | 2021-02-11 | 日商中外製藥股份有限公司 | ４環性化合物的非晶質體 |
| RS62421B1 (sr) | 2014-12-05 | 2021-10-29 | Aragon Pharmaceuticals Inc | Anti-kancerogeni sastavi |
| CN114886852A (zh) * | 2014-12-05 | 2022-08-12 | 阿拉贡药品公司 | 抗癌组合物 |
| WO2016090101A1 (en) | 2014-12-05 | 2016-06-09 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
| EA201892828A1 (ru) | 2016-06-03 | 2019-05-31 | Арагон Фармасьютикалз, Инк. | Противораковые композиции |
| KR20210023987A (ko) | 2018-06-20 | 2021-03-04 | 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. | Arn-509의 결정형, 그 제조방법 및 그 용도 |
| EP3811932A1 (en) | 2019-10-22 | 2021-04-28 | Zentiva K.S. | Dosage form of apalutamide |
-
2015
- 2015-12-03 CN CN202210133724.8A patent/CN114886852A/zh active Pending
- 2015-12-03 EP EP15817641.2A patent/EP3226841B1/en active Active
- 2015-12-03 CA CA2969656A patent/CA2969656A1/en active Pending
- 2015-12-03 MX MX2017007203A patent/MX387933B/es unknown
- 2015-12-03 PL PL15817641.2T patent/PL3226841T3/pl unknown
- 2015-12-03 AU AU2015358490A patent/AU2015358490B2/en active Active
- 2015-12-03 SM SM20240518T patent/SMT202400518T1/it unknown
- 2015-12-03 MA MA41107A patent/MA41107B1/fr unknown
- 2015-12-03 EP EP24202355.4A patent/EP4494636A3/en active Pending
- 2015-12-03 UA UAA201707020A patent/UA120950C2/uk unknown
- 2015-12-03 BR BR112017011788A patent/BR112017011788A2/pt not_active Application Discontinuation
- 2015-12-03 CR CR20170216A patent/CR20170216A/es unknown
- 2015-12-03 NZ NZ770528A patent/NZ770528A/en unknown
- 2015-12-03 JP JP2017529604A patent/JP6937692B2/ja active Active
- 2015-12-03 HR HRP20241719TT patent/HRP20241719T1/hr unknown
- 2015-12-03 MD MDE20170152T patent/MD3226841T2/ro unknown
- 2015-12-03 ES ES15817641T patent/ES2996833T3/es active Active
- 2015-12-03 HU HUE15817641A patent/HUE069689T2/hu unknown
- 2015-12-03 WO PCT/US2015/063661 patent/WO2016090098A1/en not_active Ceased
- 2015-12-03 RS RS20241412A patent/RS66323B1/sr unknown
- 2015-12-03 US US15/533,188 patent/US20170360754A1/en not_active Abandoned
- 2015-12-03 EA EA201791222A patent/EA201791222A1/ru unknown
- 2015-12-03 KR KR1020177018239A patent/KR102348320B1/ko active Active
- 2015-12-03 SG SG11201704267VA patent/SG11201704267VA/en unknown
- 2015-12-03 KR KR1020207035390A patent/KR20200141533A/ko not_active Ceased
- 2015-12-03 CN CN201580066233.4A patent/CN106999431B/zh active Active
- 2015-12-04 TW TW109112959A patent/TWI754258B/zh active
- 2015-12-04 AR ARP150103982A patent/AR102926A1/es not_active Application Discontinuation
- 2015-12-04 TW TW104140822A patent/TWI702966B/zh active
-
2017
- 2017-05-16 IL IL252323A patent/IL252323B/en active IP Right Grant
- 2017-05-25 PH PH12017500964A patent/PH12017500964A1/en unknown
- 2017-05-29 CL CL2017001371A patent/CL2017001371A1/es unknown
- 2017-06-05 MX MX2021013965A patent/MX2021013965A/es unknown
- 2017-06-05 CO CONC2017/0005572A patent/CO2017005572A2/es unknown
-
2020
- 2020-04-23 JP JP2020076516A patent/JP7174006B2/ja active Active
- 2020-12-29 IL IL279833A patent/IL279833B/en unknown
-
2021
- 2021-03-30 AU AU2021201979A patent/AU2021201979B2/en active Active
-
2023
- 2023-03-29 US US18/192,244 patent/US20230233529A1/en not_active Abandoned
- 2023-05-02 AU AU2023202710A patent/AU2023202710A1/en not_active Abandoned
-
2024
- 2024-05-10 US US18/660,698 patent/US12303493B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41107A (fr) | Compositions anti-cancéreuses | |
| DK3361870T3 (da) | Fungicidsammensætninger | |
| DK3215173T3 (da) | Glycopeptidsammensætninger | |
| LT3226842T (lt) | Priešvėžinės kompozicijos | |
| LT3226843T (lt) | Priešvėžinės kompozicijos | |
| DK3151672T3 (da) | Forbedrede t-celle-sammensætninger | |
| DK3140008T3 (da) | Hurtigtvirkende insulinsammensætninger | |
| LT3240415T (lt) | Fungicidinės kompozicijos | |
| DK3040326T3 (da) | Haloolefin-baseret sammensætning | |
| DK3089741T3 (da) | Farmaceutiske sammensætninger omfattende azd9291 | |
| FR3024363B1 (fr) | Composition thermogelifiable | |
| PL3034554T3 (pl) | Kompozycje poliamidowe | |
| BR112017001922A2 (pt) | composições fungicidas | |
| DK3250182T3 (da) | Dispergible sammensætninger | |
| DK3334726T3 (da) | Plinabulinsammensætninger | |
| PL3015500T3 (pl) | Kompozycje poliamidowe | |
| PL2924070T3 (pl) | Kompozycje poliamidów | |
| MA45090A (fr) | Compositions anticancéreuses | |
| DK3129007T3 (da) | Vaccinesammensætninger | |
| PT3200772T (pt) | Composições farmacêuticas compreendendo alpelisib | |
| CL2017000639A1 (es) | Composición | |
| DK3322295T3 (da) | Sammensætning | |
| DK3215127T3 (da) | Sammensætninger omfattende cyclosporin | |
| DK3316857T3 (da) | Multifasiske sammensætninger | |
| DK3393254T3 (da) | Sammensætning |